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Objective: It is important for psychiatrists to be aware of certain inborn errors of metabolism (IEMs) as these rare
disorders can present as psychosis, and because definitive treatments may be available for treating the underlying
metabolic cause. A systematic review was conducted to examine IEMs that often present with schizophrenia-like
symptoms.
Data sources: Published literature on MEDLINE was assessed regarding diseases of homocysteine metabolism
(DHM; cystathionine beta-synthase deficiency [CbS-D] and homocysteinemia due to methyltetrahydrofolate
reductase deficiency [MTHFR-D]), urea cycle disorders (UCD), acute porphyria (POR), Wilson disease (WD),
cerebrotendinous-xanthomatosis (CTX) and Niemann-Pick disease type C (NP-C).
Study selection: Case reports, case series or reviews with original data regarding psychiatric manifestations
and cognitive impairment published between January 1967 and June 2012 were included based on a
standardized four-step selection process.
Data extraction: All selected articles were evaluated for descriptions of psychiatric signs (type, severity, natural
history and treatment) in addition to key disease features.
Results: A total of 611 records were identified. Information from CbS-D (n = 2), MTHFR-D (n = 3), UCD (n = 8),
POR (n = 12), WD (n = 11), CTX (n = 14) and NP-C publications (n = 9) were evaluated. Six non-systematic literature
review publications were also included. In general, published reports did not provide explicit descriptions of
psychiatric symptoms. The literature search findings are presented with a didactic perspective, showing key features
for each disease and psychiatric signs that should trigger psychiatrists to suspect that psychotic symptoms may
be secondary to an IEM.
Conclusion: IEMs with a psychiatric presentation and a lack of, or sub-clinical, neurological signs are rare, but
should be considered in patients with atypical psychiatric symptoms.
Keywords: Inborn errors of metabolism, Organic psychosis, Schizophrenia-like symptoms, Atypical psychosisIntroduction
A range of medical conditions may be associated with
schizophrenia-like psychosis [1]. The landmark review of
psychosis associated with organic disorders by Davison
and Bagley, which utilized the 1957 WHO operational cri-
teria for schizophrenia, highlighted a number of disorders* Correspondence: olivier.bonnot@chu-nantes.fr
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exceeded chance [2]. Many of the disorders identified
showed pathology in the temporal lobe and diencephalon.
A large study of 268 consecutive patients with first-
episode psychosis found that 6% had organic cerebral
disease that was potentially causally linked with psychi-
atric symptoms [3], which emphasizes the importance of
a thorough diagnostic evaluation to exclude underlying
medical illness at first presentation. Recently, more than
60 different congenital conditions associated with psych-
osis were reviewed. Interestingly, some of them are notLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Bonnot et al. Orphanet Journal of Rare Diseases 2014, 9:65 Page 2 of 14
http://www.ojrd.com/content/9/1/65associated with dysmorphia, mental retardation or prom-
inent neurological features that may otherwise trigger a
search for an organic cause of illness [4].
The diagnosis of medical or neurological illnesses
underlying psychosis is of great importance as many of
these conditions are progressive or fatal, associated with
significant additional medical comorbidity, and may be
partially or entirely reversible with definitive treatment.
Inborn errors of metabolism (IEMs) represent a particu-
lar focus for research as they are frequently under-
detected or misdiagnosed, a number are treatable, and
new diagnostic methods and therapies have become
available.
IEMs are a group of diseases that generally result from
the absence or deficiency of an intracellular component
of a metabolic pathway (usually, but not exclusively, an
enzyme), which may lead to altered intracellular synthe-
sis and catabolism [5]. There are hundreds of IEMs, and
many remain poorly characterized. Most result in clin-
ical disease due to the accumulation of substances that
are toxic to, or interfere with, normal cellular function,
or which may be due to the effects of a reduced ability
to synthesize essential compounds.
The overall incidence of IEMs has been estimated to
be approximately 40 cases per 100 000 live births [6].
However, this rate may be an underestimation, as new
disorders continue to be discovered and characterized
and because diagnostic techniques continue to improve
in sensitivity and accuracy.
Up to 80% of IEMs are diagnosed during childhood,
but an increasing recognition of late-onset presentations
has recently raised awareness and diagnoses of adult-onset
forms [7]. A number of adult-onset IEMs are associated
with schizophrenia-like symptoms, including diseases of
homocysteine metabolism (DHM), urea cycle disorders
(UCD), porphyria (POR), Wilson disease (WD), cerebro-
tendinous xanthomatosis (CTX) and Niemann-Pick dis-
ease type C (NP-C) [7].
This article reports findings from a systematic literature
review and provides a guide for the diagnosis of treatable
IEMs associated with schizophrenia-like symptoms based
on the review findings. The major features of IEMs that
can be associated with psychosis are summarized, and a
diagnostic algorithm to assist psychiatrists in the detection




A meeting was held in mid-2012 to decide which IEMs
associated with psychosis are currently treatable, with
the aim of conducting a systematic bibliographic search
to address the clinical challenges associated with these
conditions. Based on a consensus reached during thatmeeting, the following seven IEMs were chosen as a
focus for this review: homocysteinemia due to methyltet-
rahydrofolate reductase deficiency (MTHFR-D), cystathio-
nine beta-synthase deficiency (CbS-D), UCD, POR, WD,
CTX and NP-C.
Literature search methodology and data sources
The public MEDLINE database was searched according
to a standard four-step protocol, as described in the
following sections and summarized in Figure 1.
Identification
All terms, including complete names and abbreviations
for MTHFR-D, CbS-D, UCD, POR, WD, CTX and NP-C
were searched alongside the generic tag, ‘psy*’ using End-
Note X5 software (Thomson Reuters), which enabled
the identification and deletion of any duplicates. In total,
708 potentially relevant records published between
January 1967 and June 2012 were identified, from which
97 duplicate records were removed. Seven separate
EndNote databases were created – one for each IEM. The
numbers of articles for each IEM database were:
MTHFR-D (n = 12); CbS-D (n = 6); UCD (n = 15);
POR (n = 75); WD (n = 451); CTX (n = 15); and NP-C
(n = 31). Six non-systematic literature reviews were
also identified and included [7-12]. A total of 611 re-
cords were collated for screening.
Screening
Two groups worked separately in screening abstracts
from relevant articles from the literature review (Group
1: M. Walterfang and H.H. Kluenemann. Group 2: O.
Bonnot, D. Cohen, Sylvie Tordjman and F. Sedel). Case
reports, case series with original data regarding psy-
chiatric manifestations and cognitive impairments, and
previous reviews containing relevant data were selected.
Articles were excluded from full text analysis (see ‘Eligi-
bility’ stage) according to the following exclusion criteria:
1) the article mentioned psychiatric manifestations with-
out data pertaining to any of the seven chosen treatable
diseases; 2) an unrelated article, mentioning an IEM
without describing psychiatric presentations; 3) literature
reviews not containing any new data and; 4) data already
reported elsewhere. Screening excluded 26 of the initial
records from the POR database and 400 records from
the WD database. In cases where the two analysis
groups did not agree, records were kept and included in
the next step.
Eligibility
The same two analysis groups accessed the full texts of
all remaining articles (n = 185) and checked them further
for eligibility according to the same exclusion criteria
used in the abstract screening stage. The numbers of
Figure 1 Summary of literature review process.
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MTHFR-D (n = 12), CbS-D (n = 6), UCD (n = 15), POR
(n = 49), WD (n = 51), CTX (n = 15) and NP-C (n = 31).
The six previous reviews were also kept.
Inclusion
Among the eligible records, information on key IEM dis-
ease features as well as psychiatric manifestations was
included from the following numbers of publications,
per database: MTHFR-D (n = 3); CbS-D (n = 2); UCD
(n = 8); POR (n = 12); WD (n = 11); CTX (n = 14) and;
NP-C (n = 9). Including the six previous reviews, this
brought the final total of source articles to 59.
Results
To understand the metabolic pathways implicated in these
disorders, we will provide an explanation in the text
referring directly to the cited diseases. For figures and
complete presentation, we refer the reader to the KFGG
website which illustrates theses pathways in detail [13].
Disorders of homocysteine metabolism (DHMs)
CbS-D and MTHFR-D are two key DHMs that com-
monly feature psychiatric signs.
Key features of CbS-D
Homocysteinuria due to CbS-D is characterized by the
involvement of the ocular, skeletal, central nervous and
vascular systems. Prevalence is estimated around 1/344
000 birth in countries were systematic search of CbS
deficiency is provided for every newborn, however recent
data from systematic search for CbS mutation showimportant prevalence up to 1/20 000 [14]. Two articles
that addressed psychiatric symptoms and psychosis were
identified [15,16]. The disease is an autosomal recessive
disorder of methionine metabolism, caused by mutations
in the CbS gene (21q22.3). CbS normally converts homo-
cysteine to cystathionine in the trans-sulfuration path-
way of the methionine cycle, and requires pyridoxal
5-phosphate as a cofactor. The other two cofactors
involved in methionine remethylation include vitamin
B12 and folic acid. Clinical diagnosis of CbS-D is con-
firmed by blood amino acid analysis (including total ho-
mocysteine measurement), assays of CbS enzyme activity,
or screening for CbS mutations.
Patients appear normal at birth but display a progres-
sive disease course if left untreated. Eye anomalies
include ectopia lentis (in 85% of cases) and high myopia.
Skeletal changes include genu valgum and pes cavus,
followed by dolichostenomelia, pectus excavatum or car-
inatum, kyphoscoliosis and osteoporosis. A Marfan-like
body habitus may occur, with tall stature and arachno-
dactyly. Thromboembolism affecting both large and small
arteries and veins is the most striking cause of morbidity
and mortality, and affects 25% of individuals by the age of
15 years. While some individuals have a normal IQ,
mental retardation is common and, when present, may
progress if the disorder is left untreated. Brittle hair and
livedo reticularis have also been reported.
Psychiatric signs associated with CbS-D
In one of the few studies in this field, psychiatric illness
was found in 51% of cases overall, with symptoms falling
into four diagnostic categories: episodic depression (10%),
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disorder (5%), and personality disorder (19%) [15]. In the
same study, aggressive behavior and other conduct
disorders were particularly common among patients with
mental retardation and those who were nonresponsive to
vitamin B6. In some cases, psychiatric symptoms may
be the initial presenting symptom with no neurological
signs [16].
Key features of MTHFR-D
MTHFR-D is another autonomic recessive trait, and is
caused by mutations in the 5,10-methylenetetrahydrofo-
late reductase (MTHFR) gene (1p36.3). MTHFR defi-
ciency results in abnormal intracellular folic acid
metabolism, and prevents reduction of 5–10 methylene-
tetrahydrofolate to 5-methyltetrahydrofolate – the me-
thyl donor for the remethylation of homocysteine into
methionine. As a result, the disorder leads to MTHFR-D
and consequently to homocysteinuria and hypomethio-
ninemia. To our knowledge prevalence is unknown.
The onset of MTHFR-D usually occurs during the first
year of life, characterized by severe neurological signs,
recurrent apnea, microcephaly and convulsions without
megaloblastic anemia. However, there are some forms with
onset during childhood, adolescence or adulthood that
present with mental regression, ataxia and schizophrenia-
like psychosis. Other symptoms such as sub-acute degener-
ation of the spinal cord have been reported.
Diagnoses of DHM are made through analysis of
amino acids by chromatography and total plasma
homocysteine measurement; an elevated level is defined
at >100 micromol/L [17]. Methionine levels may be useful,
as they are decreased in MTHFR-D and increased in
CbS-D.
There are currently three recognized treatment modal-
ities for DHM. For pyridoxine-responsive patients, treat-
ment with pharmacological doses of pyridoxine combined
with folic acid and vitamin B12 supplements is recom-
mended. In pyridoxine non-responsive patients, the treat-
ment should comprise a methionine-restricted, cysteine-
supplemented diet in combination with the pyridoxine,
folic acid and vitamin B12 supplementation. Betaine
anhydrous is a methyl donor that may lead to lowering of
homocysteine levels in MTHFR-D patients, and can be
used as an adjunct to such a diet.
Homocysteine is cleared by transulfuration to cysteine
and glutathione, an important antioxidant. Transulfura-
tion requires vitamins B6 and B12. Treatment with vita-
min B6, a precursor of homocysteine, can be effective in
treating psychiatric symptoms if instituted early [7].
Psychiatric signs associated with MTHFR-D
Three articles were identified from the systematic literature
review [18-20]. Psychiatric symptoms are not uncommonin MTHFR-D, and may be the presenting symptom [18].
Their onset may be acute or may follow a more insidious
course. Acute manifestations occur mainly after surgery,
and present with visual and/or auditory hallucinations,
thought disorder and delusions [18]. Roze and colleagues
describe two siblings (16- and 24-year-old women) with
presumed late-onset MTHFR-D. Three years after the
diagnosis of her older sister, the 16-year-old sister was ini-
tially seen with a 3-month history of dissociative symptoms
and delusions of persecution with visual and auditory
hallucinations. One month prior to hospital admission, she
had also developed an unsteady gait and urinary incontin-
ence. She was previously healthy and had been an average
student. Physical examination on admission showed only
an areflexic paraparesis with an extensor plantar response
on the right side and impaired vibration and position sense
in the lower limbs. Diagnosis was made because her sister
was known to have the disease. Combined daily treatment
with intravenous hydroxocobalamin (2 mg), oral betaine
(9 g), L-carnitine (3 g), and folinic acid (10 mg) was started,
and a dramatic clinical improvement, with the recovery of
arm function and the disappearance of psychotic features
and lethargy, was observed after 6 weeks.
In a different approach, a recent meta-analysis examin-
ing the association between MTHFR gene polymorphisms
and psychiatric disorders demonstrated a strong associ-
ation between the MTHFR C677T gene variant and uni-
polar depression, schizophrenia and bipolar disorder, with
odds ratios of 1.36, 1.44 and 1.82, respectively [20]. Not-
ably, the metabolic syndrome secondary to antipsychotic
medication may be more frequent in patients with redu-
ced MTHFR activity associated with schizophrenia-like
psychosis [21].
It is well documented that aberrant methylated com-
pounds are linked to mental state and behavior. A recent
review of the ‘one-carbon metabolism hypothesis’
described a range of factors that can contribute to folate
and/or vitamin B12 deficiency [22]. Moreover, folic acid
is a water-soluble B vitamin involved in the synthesis,
repair and methylation of DNA, leading to epigenetic
regulation of crucial developmental genes implicated in
the pathogenesis of schizophrenia [23,24]. Deficiency
of B vitamins leads to an increased level of homocyst-
eine, which is a highly toxic metabolite to neural and
vascular development [25]. Elevated serum levels of
homocysteine have also been shown to be associated
with schizophrenia, although the evidence is far from
conclusive [26,27].
Urea cycle disorders (UCDs)
Key features
The urea cycle is the metabolic process by which the
body eliminates nitrogen. Six enzymes take part in this
process; a deficiency of any one of them disrupts this
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the body in the form of ammonia. The six UCDs include
deficiency of: 1) carbamyl phosphate synthetase; 2)
n-acetylglutamate synthetase; 3) ornithine transcarba-
mylase; 4) argininosuccinic acid synthetase (also called
citrullinemia); 5) argininosuccinase acid lyase and; 6) argi-
nase. UCD has an estimated incidence of 1:8.000 [28].
If the enzyme deficiency is severe, symptoms will be
present at birth and can present as irritability, nausea
and vomiting followed by lethargy, seizures and poor
muscle tone. If left untreated, patients can develop
respiratory distress or fall victim to coma or premature
death due to pathological levels of ammonia in the blood.
If the enzyme deficiency is partial, symptom onset may
not occur until childhood or adulthood. In such cases,
symptoms may include nausea and vomiting associated
with headache and a clouded sensorium in the context
of infection or a high-protein diet. Medications may
worsen or trigger the disease, particularly corticosteroids
and sodium valproate.
There is no cure for UCDs, although prompt diagnosis
allows measures to be taken that can reduce the conse-
quences of hyperammonemia. Measurement of plasma
ammonemia is key to the diagnosis of UCDs, and treat-
ment consisting of a protein-restricted diet and special
supplements is essential [29]. In addition, several medica-
tions including sodium benzoate, sodium phenylacetate
and sodium phenylbutyrate can bind with ammonia and
remove it from the circulation. Hemodialysis may re-
present an alternative treatment, especially in emergency
situations [30].
Psychiatric signs
Eight relevant articles were identified in the literature
review [31-38]. Arn and colleagues [31] reported a 21-
year-old white woman who presented 8 days postpartum
with headache and confusion, and became uncommu-
nicative. She was admitted to a psychiatric hospital and
diagnosed with postpartum depression. Within 24 hours
of admission (11 days postpartum) she became comatose
and had generalized tonic–clonic seizures, decorticate
posturing, and papilledema. She was treated successfully
with hemodialysis and received intravenous sodium
benzoate and arginine hydrochloride. Enns and collea-
gues reported a similar case, suggesting that UCD may
present initially with postpartum psychiatric symptoms
and may represent an under-recognized cause of ‘post-
partum psychosis.’ [32]
Interestingly, late-onset (between 13 and 48 years of
age in our review) UCD may present with behavioral
and hallucinatory psychiatric and organic signs, often
featuring vomiting, which is clearly a key trigger sign for
the consideration of UCD in psychiatric situations [35-37].




The PORs comprise a group of eight hereditary meta-
bolic diseases characterized by intermittent neurovisceral
manifestations, cutaneous lesions, or the combination of
both. All porphyrias are caused by a deficiency in one of
the enzymes of the heme biosynthesis pathway. These
deficiencies result in an accumulation of porphyrins
and/or their precursors – delta-aminolevulinic acid (ALA)
and porphobilinogen (PBG) – in the liver or bone marrow.
Neurological manifestations are caused by the neurotoxic
effects of these precursors, particularly ALA. Prevalence is
estimated around 0.54:100 000 [39].
Enzyme deficiencies in the porphyrias result from
mutations of the correspondingly coded genes, and trans-
mission of hereditary porphyrias occurs in either an auto-
somal dominant fashion with weak penetrance, or in a
recessive manner with complete penetrance.
Clinical signs of disease usually appear in adulthood,
although some porphyrias affect children. Porphyrias are
classified into two groups – hepatic and erythropoietic –
according to the main location of the metabolic anomaly.
Chronic hepatic porphyrias and erythropoietic porphyrias
manifest with bullous cutaneous lesions or acute pain in
areas exposed to the sun, without neurological symptoms.
However, neuro-visceral attacks occur in patients with
acute hepatic porphyrias, manifesting as intense ab-
dominal pain (often associated with nausea, vomiting and
constipation), and neurological and psychological symp-
toms. Two acute hepatic porphyrias (variegate porphyria
and hereditary coproporphyria) may also present with cu-
taneous photosensitivity.
Diagnosis is mainly based on the measurement of por-
phyrins and their precursors in biological samples such
as urine, stools and blood. The key diagnostic procedure
is the measurement of ALA and PBG in urine. Genetic
counseling should be offered to affected families to iden-
tify individuals susceptible to developing and transmitting
the disease. Acute attacks should be treated urgently
with an injection of human hemin and/or perfusion
of carbohydrates.
Psychiatric signs
Twelve relevant articles were included from the systematic
literature review. Psychiatric manifestations are widely
known and well documented [40-43], occurring in 24–
70% of patients in acute porphyria series [44,45]. The
most common manifestations reported are delirium,
psychosis and depression, with some authors suggesting
that 40% of acute porphyrias present with delirium and
hallucinations [46].
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Malhotra reported the case of a 13- year-old boy with
six episodes of psychosis with various presentations, in-
cluding delusions, hallucinations, hypomania and catato-
nia, but with no obvious organic signs [43]. Crimlisk
described three noteworthy cases. The first was that of a
53-year-old woman with a history of cognitive decline
since the age of 20, and episodes of visual hallucinations,
ataxia, abdominal pain and weight loss; diagnosis was
achieved after an acute vomiting episode at 53 years of
age. A 52-year-old woman with a history of episodic psy-
chiatric disturbance with associated ideas of reference,
auditory hallucinations, emotional lability and abdominal
pain was also described, with episodes tending to occur
pre-menstrually. The third case was a young boy with a
history of generalized pain, vesicular rash, fever and nau-
sea, in whom a diagnosis was made when psychiatric
symptoms (paranoid schizophrenia) appeared.
Finally, Mandoki and Summer reported a sub-acute
psychiatric dysphoric presentation with emotional labil-
ity and aggression, as well as headaches and abdominal
pain, in a 9-year-old girl who had a history of aggressive
behavior and early anorexia [47]. The patient was diag-
nosed with coproporphyria – a subtype of porphyria in
which psychiatric signs (labile mood and psychosis) have




WD is an autosomal recessive disorder with a prevalence
of 6 per 100 000 of the general population [39]. A muta-
tion in the ATP7B gene coding for a key copper trans-
port protein leads to copper accumulation in the liver,
brain, kidney and skeletal system, caused by reduced
excretion in the bile [52].
In approximately half of patients, computerized
tomography reveals characteristic hypodensities in the
basal ganglia [53]. Virtually all patients show magnetic
resonance imaging (MRI) abnormalities, including T2-
weighted hyperintensities in the thalamus, brainstem
and lenticular nuclei [54]. Functional imaging gener-
ally shows significant hypometabolism in the lenticular
nuclei [55].
Classically, symptoms of WD appear between the ages
of 6 and 20 years. Approximately one-third of patients
initially present with hepatic disease, one-third with neu-
rological symptoms, and one-third with psychiatric
symptomatology. Kayser-Fleischer ring is seen in some
patients during ophthalmological examinations. Between
one- and two-thirds of patients report psychiatric symp-
toms at initial presentation [56-58]. Psychiatric signs are
present in almost 50% of patients at any one time [59],
and present before motor signs in 20% of cases; upto half of patients may be seen initially by a psych-
iatrist [60].
Psychiatric signs
Eleven relevant case reports or case series (psychiatric or
general including psychiatric patients) were identified,
and data from most of these were included in a large
review [57]. Four main psychiatric symptom clusters have
been identified: mood and affective change; behavior and
personality change; psychosis and; cognitive impairment
[61]. Personality changes are very common, particularly
irritability and aggression [56,62]. Mood disturbance, in-
cluding both depression and mania, is the most common
formal neuropsychiatric illness [63-67]. Psychosis, delu-
sional states and catatonia, while less frequent in WD, can
be extremely disabling [56,57,60,61,68]. Schizophrenia-like
symptoms were reported to be present in up to 10% of
patients [63], but were less prevalent in one case series
(2.4%) [69]. Whilst delusions in WD have been reported
to be uncommon [60], a number of psychotic presenta-
tions meeting criteria for delusional disorder have recently
been described [70-73].
Deteriorating academic performance or work function
is another key neurological feature of WD. Neurologic-
ally symptomatic patients display a range of cognitive
difficulties including impairments of executive function,
aspects of memory and visuospatial processing [59,74,75].
In contrast, no such deficits are found in neurologically
asymptomatic patients [76]. Lesions within the basal
ganglia seem to be of central importance in cognitive
change due to their interruption of frontal-subcortical
circuits [76,77].
After initiating treatment with chelation therapy, the
disease often stabilizes or improves, but disease progres-
sion during treatment is more likely for neuropsychiatric
symptoms than for hepatic symptoms [78]. Resolution of
neuropsychiatric illness following chelation has been
reported [67,73,79,80].
The use of neuroleptic medication may be problematic
due to the increased risk of movement disorder side
effects in the setting of degenerative basal ganglia disease
[81-84]. However, some reports suggest the relatively
safe use of atypical medications such as olanzapine,
risperidone, quetiapine and clozapine, which each
have a lower propensity to cause movement disorders
[72,83,85,86]. Nevertheless, these agents should be
used with caution because of the increased risk of
agranulocytosis in the presence of hypersplenism or
penicillamine treatment.
Treatment of mania with mood stabilizers can be
difficult because valproate or carbamazepine may be
contraindicated in the presence of significant hepatic
impairment [84]. Lithium may also be contraindicated in
the presence of renal tubular acidosis [84], although
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ise has been reported [86,87].
Electroconvulsive therapy (ECT) has been successfully
used in cases of catatonia [88], psychosis [89] and depres-
sion [90-92].
Depression has been reported as responding to both
tricyclic antidepressants and selective serotonin reuptake
inhibitors [91-93], although treatment-resistance to trad-
itional antidepressants has also been described [91]. A
manic switch in response to antidepressant therapy has
also been described in one patient [93].
Cerebrotendinous xanthomatosis (CTX)
Key features
CTX is an autosomal recessive disease of bile acid syn-
thesis. It is caused by mutations in the CYP27A1 gene,
which is localized on the long arm of chromosome 2
and codes for the mitochondrial enzyme, sterol-27-
hydroxylase. This enzyme is involved in the synthesis of
chenodeoxycholic and cholic acids from cholesterol. The
metabolic block resulting from the mutant gene causes a
progressive storage of cholesterol and its poorly soluble
by-product, cholestanol, which is deposited in many
tissues including the brain and tendons [94]. A recent
review found more than 300 patients with CTX reported
worldwide, and identified 50 different mutations in the
CYP27A1 gene associated with this disease [95]. Preva-
lence is estimated around 2:100 000 [96].
Clinical presentations of CTX are quite variable. The
initial symptoms typically begin in childhood with non-
specific mild mental retardation, juvenile cataract, chronic
diarrhea or epilepsy. Progressive neurological deterior-
ation follows in adolescence or adulthood with acute
psychiatric signs [10,97], progressive spastic paraparesis,
cerebellar ataxia, polyneuropathy, epilepsy and cognitive
deficits leading to severe handicap or death. These neuro-
logical signs can be accompanied by the appearance of
tendon xanthomata, which are usually visible at the level
of the Achilles’ tendons. An MRI of the brain typically
shows a specific pattern with high signals in the dentate
nuclei of the cerebellum on T2-weighted sequences [98].
Chenodeoxycholic acid is the primary treatment for
CTX. This agent blocks the accumulation of cholestanol
by replenishing the pool of bile acid in the liver and
hepatic circulation, and shuts down the abnormal hep-
atic bile acid synthesis pathway. Although it is efficient
at normalizing circulating levels of cholestanol, and
clearly stabilizes disease progression, it does not improve
already existing neurological signs. In addition, xantho-
mata do not decrease in size.
Psychiatric signs
Fourteen articles were identified in the systematic litera-
ture review [10,97]. Psychiatric manifestations in CTXhave only been described in sporadic reports and two
patient series [97,99-111]. Unfortunately, many of these
cases are poorly documented and do not contain a sys-
tematic psychiatric evaluation.
Acute psychotic episodes have been described, but
most psychiatric symptoms are non-specific and occur
during childhood and/or adolescence [10,97]. Hyperactiv-
ity is the most common syndrome seen during youth, and
is associated with cognitive impairments in speech and
comprehension [112].
The Dotti et al. series described 11/13 patients (85%)
with psychiatric symptoms [Note: please confirm that 11
patients out of the 13 studied had psychiatric symptoms,
as queried]: five with behavioural changes, four with
psychosis and two with depression [107], suggesting an
over-representation of psychiatric disorders in this po-
pulation. This contrasts with the documented rarity of
psychiatric signs in CTX (around 10%). In the only small
series specifically focusing on the psychiatric spectrum
of CTX, Berginer et al. reported four patients with dis-
parate psychiatric syndromes, including irritability and
personality changes with hypersexuality, atypical psych-
osis and paranoid delusions, and severe catatonia [97].
Diagnoses of CTX were made on the basis of pes cavus
and Achilles xanthomata in all patients, and caratacts
and cognitive impairment in two cases.
Two siblings were recently described with an early
psychiatric presentation comprising attention deficit
hyperactivity disorder (ADHD) and oppositional defiant
disorder (ODD) associated with mild intellectual disabil-
ity [112]. In both patients, treatment with chenodeoxy-
cholic acid improved externalizing symptoms, and a
partial recovery of cognitive impairment was observed.
Niemann Pick disease type C (NP-C)
Key features
NP-C is a pan-ethnic, autosomal recessive neurodegen-
erative disease with an incidence estimated between 1
case per 150 000 and 1 case per 120 000 live births
[113,114]. The disease is characterized by a variety of
progressive, disabling neurological symptoms including
clumsiness, limb and gait ataxia, dysarthria, dysphagia
and cognitive deterioration [113,115].
NP-C is associated with mutations of the NPC1 and
NPC2 genes, with no primary defect in catabolic enzymes.
NPC1 gene mutations are present in 95% of cases and
NPC2 mutations are present in approximately 4%. At the
cellular level, these mutations give rise to characteristic
abnormalities in the intracellular transport of cholesterol,
glycosphingolipids and sphingosine. Impaired function of
the NPC1 and NPC2 gene products, which normally func-
tion cooperatively in intracellular lipid transport, leads to
the accumulation of these lipids in the late-endosomal/
lysosomal intracellular compartment, and excess build up
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bis(monoacylglycero)-phosphate, glycosphingolipids and
sphingosine are stored in excess in the liver and spleen,
while levels of glucosylceramide, lactosylceramide and,
above all, GM2 and GM3 gangliosides are markedly
increased in the brain [116].
NP-C has an extremely heterogeneous clinical presen-
tation characterized by a wide range of symptoms that
are not specific to the disease, and which arise and pro-
gress over varied periods of time [113,117]. This compli-
cates diagnosis, and is likely an important factor in the
under-detection of the NP-C and, in some cases, its mis-
diagnosis. In the first decade of life, the most common
presentations are neurological, although early-onset
patients are often diagnosed based on isolated systemic
manifestations (e.g. neonatal jaundice, splenomegaly).
Many cases are also diagnosed in adulthood, sometimes
even up to the seventh decade of life [118].
The age at onset of neurological symptoms has a major
influence on disease progression; [119] if neurological
symptoms arise early in life the rate of deterioration is
generally faster and premature death occurs sooner. Pa-
tients with the perinatal-onset form present during the
first 3 months of life with an enlarged liver and spleen,
prolonged cholestasis, hydrops fetalis and/or respiratory
failure [113,114], usually without presenting neurological
signs. Infantile, juvenile and adolescent/adult forms usu-
ally present with neurological signs including progressive
ataxia, dystonia, dysarthria, dysphagia, deafness, cataplexy
or, more rarely, epilepsy. Most notably, vertical supra-
nuclear gaze palsy (VSGP) – particularly paresis of down-
gaze – is a highly specific and highly prevalent sign that
may be present at an early stage of the disease [113,115].
VSGP or discrete slowing of saccades is present in almost
all cases at some point during the disease course.
Diagnosis of NP-C requires a skin biopsy and a fibro-
blast culture in a specialized center, with the resulting
cultured cells stained with filipin (which binds excess
cholesterol) and tested for cholesterol esterification.
However, data suggest that plasma oxysterol measure-
ments may represent a simpler screening and/or diag-
nostic method in the coming years [120].
Therapy for NP-C has, until recently, been limited to
supportive measures, including pharmacotherapy to allevi-
ate neurological and psychiatric symptoms [113,115,121].
Miglustat, an iminosugar compound that reversibly in-
hibits glucosyl ceramide synthetase and thus inhibits the
formation of excess gangliosides, is a substrate-reduction
therapy that has been shown to stabilize neurological
manifestations in children and adults [122-124].
Psychiatric signs
Numerous cases of NP-C presenting with schizophrenia-
like symptoms have been reported in adolescent andadult patients, and nine case series and reports were
identified and included in this literature analysis
[125-133]. Definitive diagnoses are commonly delayed in
patients with adult psychiatric presentations of NP-C,
sometimes by up to 10 years [134].
Psychotic presentations among children and ado-
lescents with NP-C have been reported, and may be
comorbid with a pervasive developmental disorder
(PDD). Sandu et al. reported a case of an 8-year-old with
PDD who presented with auditory hallucinations and
7 years later developed a typical paranoid schizophrenic
illness that was partially responsive to risperidone [132].
One notable report described two siblings with psychosis
[131]. The male sibling presented at 16 years old with
visual and auditory hallucinations, and later developed
dysarthria and ataxia leading to a definitive diagnosis at
the age of 24 years when vertical supranuclear ophthalmo-
plegia was discovered. His sister developed schizophrenia-
like symptoms a decade later, but diagnosis was made
rapidly when she was examined for vertical supranuclear
ophthalmoplegia based on the family history. Notably, her
later onset and lower antipsychotic dosage required to
effect symptom resolution mirrored the gender dimorph-
ism seen in typical schizophrenia, which raises the possi-
bility of a gender effect in presentation and progression of
NP-C [131].
The onset of developmental delay is commonly seen
between 6 and 15 years of age in NP-C, and may result
in a learning disorder and/or impaired school perform-
ance [117,135,136]. Patients commonly display cognitive
impairments involving logical thinking and abstraction,
impaired attentional processes, poor working memory,
word retrieval difficulties, and a lack of interpersonal
‘distance’ [121,136]. The typical cognitive profile in adult
patients is one of significant executive dysfunction and
impaired working memory [115,136].
Discussion
This article is the first systematic review in this field.
Widely unknown and neglected by psychiatrists, IEMs
represent a growing field in research that interfaces with
clinical psychiatry due to the fact that a number of disor-
ders may initially present to psychiatrists. New treat-
ments are available for a number of these diseases [137].
One key finding of this literature review is that the
clinical signs of IEMs are poorly documented in terms
of both quantity (only 63 articles with original data for
seven different disorders) and quality (non-systematic
clinical evaluations, lack of standardized clinical scales,
sparse clinical description). A second clear finding is that
many cases of WD, MTHFR-D and NP-C are strongly
associated with psychotic illness.
It is not realistic, and probably unnecessary due to the
rarity of the association, to consider IEMs in all psychiatric
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become metabolic specialists. However, it is crucial for all
professionals working in psychiatry to be aware of the large
variety of organic disorders that may be associated with
psychiatric diseases, particularly treatable IEMs such as
those addressed in this review, and to be aware of clinical
features that may herald an underpinning organic disorder
for the patient’s psychiatric presentation.
One major difficulty in considering the association of
IEMs with psychosis is in ascribing causality. If preva-
lence rates across a number of populations are higher
than 0.8–1.0% (the general population prevalence for
schizophrenia) [138,139] it may be difficult to consider
an association with IEMs as significant as their prevalence
is more likely around 1 in 10 000. In addition, when treat-
ment of an organic disorder leads to an improvement in
psychotic symptoms, this association is strengthened, and
the Bradford-Hill criteria of strength, consistency and
temporality are met [140]. These associations may also aid
in shedding light on the potential neurobiological origins of
schizophrenia. There is a wide consensus regarding the
neurodevelopmental hypothesis of schizophrenia [141,142],
as well as the role of complex genetic determinism and
gene–environment interactions [143]. The historical asso-
ciation of a range of organic disorders with schizophrenia-
like psychosis has shed light on the role that the medial
temporal lobe and diencephalon play in the origin of
psychotic symptoms [2], and similarly the recent advance-
ment in our understanding of the neurobiology of various
IEMs has shed light on the role of anatomical disconnec-
tion and disruption to a range of neurotransmitter systems
in the genesis of psychotic illness [130].
The second major difficulty is to recognize IEMs and
to think about an organic etiology in clinical practice. In
order to help psychiatrists, it could be clinically useful to
identify psychiatric features that may trigger for the
search of organic disorder in patients with schizophre-
nia. Unfortunately, data regarding organic psychosis and
its specific associated symptoms are scarce. One study,
which was not specific for IEMs, analyzed the phe-
nomenology of 74 patients with ‘organic schizophrenia’Table 1 Atypical psychiatric features which should trigger a s
schizophrenia
First level atypical feature (atypical on their own) Seco
Confusion Acut
Visual hallucinations more important than auditory hallucinations Early
Catatonia Intel
Progressive cognitive decline Unu
Treatment resistance
Fluctuating schizophrenia core symptoms
As the validity and specificity of these atypical psychiatric signs have not yet been
neurological exam prior to further progressive screening.compared with ‘non-organic schizophrenia’ [144]. Visual
hallucinations and confusion were seen more often
among patients with organic schizophrenia, and compar-
able features have been observed in elderly schizophre-
nia patients [145,146]. A handful of inborn errors of
metabolism may cause elementary hallucination and
visual hallucinations which are associated with various
organic and psychiatric conditions [147]. Hallucinations
are a core symptom of schizophrenia and are more often
auditory or at least, auditory hallucinations are more im-
portant than visual hallucinations. We suggest therefore
that predominant visual hallucinations are highly sug-
gestive of organic disorders such as IEM. An acute onset
of psychiatric symptoms may also raise suspicion of
IEMs (e.g. UCDs, porphyria or homocysteinemia with
CbS-D). It is also notable that data indicate a high
degree of association of catatonia with organic disorders,
especially if it occurs during childhood or adolescence
[148]. An unusually high proportion of patients with
organic disorders has been reported in large series of
patients with early-onset schizophrenia, which suggests
that an early-onset of schizophrenia-like symptoms is
another indicator for possible organic origin of disease,
especially if associated with progressive cognitive decline,
which is a common feature in IEMs [149]. Finally, treat-
ment resistance is frequently associated with IEMs [150],
again suggesting its possible use as an indicator for
possible organic disease. In summary, we may suggest six
readily recognizable features that should trigger the suspi-
cion of organicity associated with schizophrenia-like
symptoms: 1) acute confusion; 2) visual hallucinations
more important than auditory hallucinations; 3) catatonia;
4) progressive cognitive decline; 5) early or acute onset
and; 6) treatment resistance (see Table 1). As the validity
and specificity of these atypical psychiatric signs have not
yet been evaluated, they are presented to raise awareness
and suggest clinical and neurological exams prior to
further progressive screening. Both atypical psychiatric
signs and main clinical/biomarker features of IEM lead us
to propose an algorithm (see Figure 2). This algorithm is
based on clinical practice of OB, HK and MW and DC.earch for inborn error of metabolism in patients with
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Figure 2 Diagnostic algorithm for diagnosing inborn errors of metabolism in patients with schizophrenia-like symptoms. Negative: If
exams are negative and suspicion is high. Positive: Could lead to diagnoses or high suspicion of specific disease. MRI = magnetic resonance
imaging; MTHFR-CbS =methylenetetrahydrofolate reductase-cystathionine beta-synthase; NP-C = Niemann-Pick disease type C; UCDs = urea cycle
disorders, WD =Wilson disease.
Table 2 Synthesis of main clinical, contextual, ophthalmologic symptoms associated with 7 treatable IEM associated
with schizophrenia-like symptoms
Disorder Clinical signs Context Eye exam Biomarkers
Wilson disease (WD) Tremor – Kayser-Fleischer ring Ceruloplasmin
Dystonia
Dysarthria
Urea cycle disorders (UCDs) Confusion Protein diet – Hyperammoniemia
Abdominal pain Post surgery
Nausea/vomiting Drugs*
Homocysteinemia (MTHFR) Ataxia – – Homocysteinemia
Mental regression Methioninemia
Homocysteinemia (CbS) Thromboembolism Protein diet Severe myopia Homocysteinemia
Scoliosis Post surgery Ectopic lens Methioninemia
Marfan-like cerebellar signs
Niemann-Pick disease type C (NP-C) Dystonia + ataxia Dysarthria Neonatal icterus Supranuclear vertical Skin biopsy
Splenomegaly Slow progression gaze palsy Filipin test
NPC1 and NPC2 gene test
Cerebrotendinous xanthomatosis (CTX) Chronic diarrhea – Juvenile cataract High cholestanol
Spastic paralysis
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in population of patients with psychiatric signs and IEM.
Further research is needed to develop a real suspicion
index from our group of atypical psychiatric signs associ-
ated with this algorithm.
Biological screening is not recommended for all patients
but only in case of high suspicion. It is also important to
know that the cost of screening for most of these disor-
ders in standard metabolic reference laboratories is usually
modest, generally consisting of serum or urine tests for
various metabolites, comparable or less than the cost of
basic neuroimaging. The costs of treating these IEMs
varies widely; from B-vitamin replacement and/or dietary
modification in a number of disorders, to more expensive
long-term treatments in disorders such as NPC, and
potential high-cost hospitalizations during metabolic crises
in UCDs and porphyria. This should however be refer-
enced against the cost of treating true schizophrenia, at a
cost of at least $USD 50000 per year [151], with at least
one third of this borne in direct treatment.
Toward atypical psychiatric signs, IEMs presents speci-
ficities and Table 2 provides a summary that encompasses
the main clinical signs of six treatable IEMs, and high-
lights the main clinical symptoms, biomarkers and context
as well as ophthalmologic signs, which occur in at least
four of the treatable IEMs.
It is important for psychiatrists and other associated
professionals to be specifically aware of potential IEMs
when patients present with such indicators (organic
signs and atypical psychiatric symptoms) of possible
organic psychosis.
Conclusions
Based on published evidence this review highlights the
role of a range of IEMs as possible underlying organic
causes of schizophrenia or schizophrenia-like syndromes.
It is important to identify such cases as some IEMs are
treatable (sometimes simply with vitamin replacement or
supplementation) and new treatments continue to appear.
Clinical studies suggest that some IEM-specific treatments
may be most effective during the early stages of disease
when psychiatric symptoms may be evident. Efficient
recognition and identification of the underlying organic
disease could therefore allow earlier initiation of specific
therapy and, possibly, improve outcomes.
Although the literature base from which to draw
conclusions is limited, clinicians managing patients pre-
senting with new-onset psychosis should pay particular
attention to IEMs as a possible underlying cause in
patients with atypical symptoms, and in the presence of
specific clinical contexts. It is hoped that this review
summarizing six easily assessed features that might
trigger suspicion of organicity in patients with psychosis
will help to detect patients with treatable IEMs as earlyas possible during their disease course. While not inten-
ded to replace specialized psychiatric or neurological
examination and measurements, our proposed algorithm
(Figure 2) is a pragmatic tool that can be used to reduce
the risk of mistaken diagnoses among patients with atyp-
ical psychiatric signs and treatable IEMs.
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